Holsinger Leslie
SEC CIK 1770821 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| QNCX | Quince Therapeutics, Inc. | EVP, Preclinical Development | 148.1K | — | — | 2 | 2022-03-03 | 2022-06-06 |
Most active insiders at QNCX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Benatti Luca | Dir | — | $173.5K |
| 2 | Hannah Brendan | COO, CCO, CBO | — | — |
| 3 | Thye Dirk | CEO, CMO, Dir | — | — |
Holsinger Leslie made no open-market trades at QNCX in the last 12 months.
Transactions 2
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-06-08 | 2022-06-06 | QNCX | Quince Therapeutics, Inc. | Holsinger Leslie | EVP, Preclinical Development | F - Tax | $2.86 | -10.9K | 148.1K | -7% | -$31.2K | |
| 2022-03-04 | 2022-03-03 | QNCX | Quince Therapeutics, Inc. | Holsinger Leslie | EVP, Preclinical Development | A - Grant | $0.00 | +155.5K | 159.0K | +4,443% | $0 |
Purchase Sale Sale after option exercise All abbreviations